4//SEC Filing
Orexigen Therapeutics, Inc. 4
Accession 0001209191-17-037271
CIK 0001382911operating
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 4:33 PM ET
Size
8.0 KB
Accession
0001209191-17-037271
Insider Transaction Report
Form 4
Cannell Thomas R
Chief Commercial Officer
Transactions
- Award
Common Stock
2017-05-31$1.55/sh+2,119$3,284→ 3,882 total
Footnotes (1)
- [F1]Shares acquired under Issuer's 2013 Employee Stock Purchase Plan.
Issuer
Orexigen Therapeutics, Inc.
CIK 0001382911
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001382911
Filing Metadata
- Form type
- 4
- Filed
- Jun 1, 8:00 PM ET
- Accepted
- Jun 2, 4:33 PM ET
- Size
- 8.0 KB